Signed in
We value your privacy
This site uses cookies to improve your browsing experience, analyze site traffic, and show personalized content.
| No holders yet. | ||||||||||
Retatrutide is an investigational, once-weekly injectable medication developed by Eli Lilly that targets three hormone receptors (GLP-1, GIP, and glucagon) to treat obesity and type 2 diabetes.